tiprankstipranks

Reata Pharmaceuticals downgraded to Neutral from Overweight at Cantor Fitzgerald

Cantor Fitzgerald analyst Charles Duncan downgraded Reata Pharmaceuticals (RETA) to Neutral from Overweight after Biogen (BIIB) agreed to acquire Reata for $172.50 per share in cash.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on RETA:

Disclaimer & DisclosureReport an Issue

1